Vanta Bioscience Ltd

Vanta Bioscience Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Vanta Bioscience Ltd

₹ 18.5 -4.64%
12 Mar - close price
vantabio.com BSE - SME: 540729
About

Incorporated in 2016, Vanta Bioscience Ltd is a full-service preclinical contract research organisation. [1]

Key Points

Business Overview:[1][2][3]
a) VBSL conducts R&D, clinical, and pre-clinical studies across genetic, animal, inhalation, and eco-toxicology.

b) It is a preclinical contract research company offering safety assessment services to clients in pharma, medical devices, nutraceuticals, feed additives, biotech, agrochemicals, cosmetics, and chemicals.

c) The company provides risk assessment services for APIs, excipients, extractables, leachables, and impurities arising from manufacturing or product degradation.

d) VBSL also offers expert services to determine health-based exposure limits, including PDE, ADE, and OEL for pharmaceutical manufacturers.

Website BSE
  • Market Cap ₹ 13.2 Cr.
  • Current Price ₹ 18.5
  • High / Low ₹ 31.3 / 15.0
  • Stock P/E
  • Book Value ₹ 27.1
  • Dividend Yield 0.00 %
  • ROCE -11.6 %
  • ROE -37.2 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Stock is trading at 0.68 times its book value

Cons

  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of -32.3% over past five years.
  • Company has a low return on equity of -27.2% over last 3 years.
  • Company has high debtors of 466 days.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Healthcare Services Healthcare Research, Analytics & Technology

Edit Columns
Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2019 Mar 2020 Sep 2020 Mar 2021 Sep 2021 Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025 Sep 2025
7.33 6.81 5.28 4.76 5.38 4.31 2.82 3.45 6.18 3.55 1.03 0.93 0.30
5.16 4.61 3.50 2.58 3.89 2.33 3.37 5.30 4.12 4.30 1.42 4.81 0.67
Operating Profit 2.17 2.20 1.78 2.18 1.49 1.98 -0.55 -1.85 2.06 -0.75 -0.39 -3.88 -0.37
OPM % 29.60% 32.31% 33.71% 45.80% 27.70% 45.94% -19.50% -53.62% 33.33% -21.13% -37.86% -417.20% -123.33%
0.00 0.11 0.00 0.03 0.02 0.40 0.01 0.68 0.03 0.08 0.04 0.07 0.00
Interest 0.97 0.98 1.01 1.13 1.14 1.20 2.48 3.40 2.85 2.90 2.14 1.92 0.88
Depreciation 0.41 0.78 0.61 0.65 0.66 0.66 1.31 1.36 1.54 2.95 1.69 2.73 0.61
Profit before tax 0.79 0.55 0.16 0.43 -0.29 0.52 -4.33 -5.93 -2.30 -6.52 -4.18 -8.46 -1.86
Tax % 31.65% 16.36% 68.75% 9.30% -106.90% 13.46% 2.08% 1.52% -0.87% -3.07% -1.20% 8.39% -2.69%
0.54 0.46 0.06 0.39 0.02 0.07 -2.56 -3.92 -0.54 -1.78 -2.07 -2.71 -1.82
EPS in Rs 0.86 0.73 0.10 0.62 0.03 0.11 -4.06 -6.21 -0.86 -2.82 -3.28 -4.29 -2.56
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
12.08 13.75 9.82 9.40 5.83 9.72 1.96 1.23
8.81 9.38 5.87 5.93 8.22 8.41 6.21 5.48
Operating Profit 3.27 4.37 3.95 3.47 -2.39 1.31 -4.25 -4.25
OPM % 27.07% 31.78% 40.22% 36.91% -40.99% 13.48% -216.84% -345.53%
0.23 0.11 0.03 0.42 0.69 0.11 0.11 0.07
Interest 1.69 1.95 2.14 2.35 5.89 5.75 4.07 2.80
Depreciation 0.71 1.19 1.25 1.32 2.67 4.50 4.42 3.34
Profit before tax 1.10 1.34 0.59 0.22 -10.26 -8.83 -12.63 -10.32
Tax % 36.36% 24.63% 23.73% 40.91% 1.75% -2.49% 5.23%
0.70 1.01 0.45 0.14 -10.44 -8.61 -13.29 -4.53
EPS in Rs 1.11 1.58 0.71 0.14 -10.27 -3.68 -7.56 -6.85
Dividend Payout % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Compounded Sales Growth
10 Years: %
5 Years: -32%
3 Years: -41%
TTM: -73%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: %
TTM: -18%
Stock Price CAGR
10 Years: %
5 Years: -37%
3 Years: -36%
1 Year: -40%
Return on Equity
10 Years: %
5 Years: -13%
3 Years: -27%
Last Year: -37%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 6.31 6.31 6.31 6.31 6.31 6.31 6.31 7.11
Reserves 15.94 17.16 17.61 17.70 11.20 8.89 4.11 12.14
13.25 17.37 35.97 44.86 57.16 60.96 70.09 30.57
3.51 7.74 9.74 12.53 10.04 9.24 5.37 7.04
Total Liabilities 39.01 48.58 69.63 81.40 84.71 85.40 85.88 56.86
17.90 20.76 29.39 36.12 57.22 54.15 55.50 41.82
CWIP 3.70 7.00 19.34 28.47 10.60 12.53 13.47 0.00
Investments 1.95 0.00 0.00 0.00 0.00 0.00 0.00 3.00
15.46 20.82 20.90 16.81 16.89 18.72 16.91 12.04
Total Assets 39.01 48.58 69.63 81.40 84.71 85.40 85.88 56.86

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
-1.04 2.34 6.97 5.28 -0.63 2.68 -2.41
-5.73 -7.59 -22.30 -17.24 -5.91 -3.31 -6.69
9.94 2.17 17.78 9.53 6.41 0.69 9.16
Net Cash Flow 3.18 -3.07 2.46 -2.43 -0.13 0.06 0.06

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 47.14 36.90 74.71 43.88 122.71 117.91 465.56
Inventory Days 2,400.15
Days Payable 1,821.31
Cash Conversion Cycle 47.14 36.90 74.71 43.88 122.71 117.91 1,044.40
Working Capital Days 260.76 259.61 91.06 -135.13 -163.40 -217.42 -2,126.68
ROCE % 8.35% 5.21% 3.77% -5.82% -4.16% -11.58%

Insights

In beta
Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Research & Development (R&D) Expenditure
INR Lakhs ・Standalone data

Log in to view insights

Please log in to see hidden values.

Login
Total Headcount (Permanent Employees)
Number ・Standalone data
Unbilled Revenue (Services Under Process/Inventory)
INR Lakhs ・Standalone data
Number of Scientists
Number ・Standalone data

Shareholding Pattern

Numbers in percentages

Sep 2020Mar 2021Sep 2021Mar 2022Sep 2022Mar 2023Sep 2023Mar 2024Sep 2024Mar 2025May 2025Sep 2025
69.93% 69.11% 69.00% 69.00% 69.36% 69.36% 69.36% 69.36% 69.36% 69.36% 72.81% 72.81%
30.07% 30.89% 31.00% 31.00% 30.64% 30.65% 30.64% 30.64% 30.64% 30.64% 27.18% 27.19%
No. of Shareholders 325361412409393394388418424408408419

Documents

Announcements

Annual reports

DRHP

Credit ratings